MDMA clinical trials in Europe: how to take part (2 recruiting)
MDMA-assisted therapy is not approved anywhere in Europe, so a regulated clinical trial is the only lawful route. A trial is research, not treatment: it may involve placebo and demanding visit schedules, and participation may bring no personal benefit.
Recruiting mdma studies
| Trial | Phase | Country | Recruiting sites | Registry entry |
|---|---|---|---|---|
| Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Pa | Phase I | Switzerland | Clinical Pharmacology & Toxicology, University Hospital Basel (Basel) | NCT07494214 |
| Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficie | — | Switzerland | University Hospital Basel (Basel) | NCT06789705 |
How taking part practically works
The route: read the trial's registry entry (criteria, visit schedule), contact the site directly (listings lag reality), then pre-screening and a screening visit. Eligibility is selective and screening may not lead to enrolment; that is a protocol outcome, not a judgment. Trial medicines and study procedures are generally free of charge (Article 92 of the EU regulation; confirm travel costs separately), participation can be ended at any time without losing entitled care, and no medication is stopped before the prescribing clinician and the investigator agree. Details: guide to joining a trial; pre-check your profile with the eligibility check.